Literature DB >> 33994176

Microfluidic technologies for drug discovery and development: friend or foe?

Katherine S Elvira1.   

Abstract

There is a point in the evolution of every new technology when questions need to be asked regarding its usefulness and impact. Although microfluidic technologies have drastically decreased the scales at which laboratory processes can be performed and have enabled scientific advances that would have otherwise not been possible, it is time to consider whether these technologies are more disruptive than enabling. Here, my aims are to introduce researchers in the broad fields of drug discovery and development to the advantages and disadvantages of microfluidic technologies, to highlight current work showing how microfluidic technologies can be used at different stages in the drug discovery and development process, to discuss how we can transfer academic breakthroughs in the field of microfluidic technologies to industrial environments, and to examine whether microfluidic technologies have the potential to cause a fundamental paradigm shift in the way that drug discovery and development occurs.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords:  artificial cells; drug discovery and development; lab-on-a-chip; microfluidic technologies; organs-on-a-chip; personalized medicine

Year:  2021        PMID: 33994176     DOI: 10.1016/j.tips.2021.04.009

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  4 in total

1.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

Review 2.  Electrochemical Signal Amplification Strategies and Their Use in Olfactory and Taste Evaluation.

Authors:  Xinqian Wang; Dingqiang Lu; Yuan Liu; Wenli Wang; Ruijuan Ren; Ming Li; Danyang Liu; Yujiao Liu; Yixuan Liu; Guangchang Pang
Journal:  Biosensors (Basel)       Date:  2022-07-26

3.  The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway.

Authors:  Kana Shimizu; Yoichi Sunagawa; Masafumi Funamoto; Hiroki Honda; Yasufumi Katanasaka; Noriyuki Murai; Yuto Kawase; Yuta Hirako; Takahiro Katagiri; Harumi Yabe; Satoshi Shimizu; Nurmila Sari; Hiromichi Wada; Koji Hasegawa; Tatsuya Morimoto
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-05

Review 4.  Artificial exosomes for translational nanomedicine.

Authors:  Yong-Jiang Li; Jun-Yong Wu; Jihua Liu; Wenjie Xu; Xiaohan Qiu; Si Huang; Xiong-Bin Hu; Da-Xiong Xiang
Journal:  J Nanobiotechnology       Date:  2021-08-12       Impact factor: 10.435

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.